Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 20/20 | 0.65 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.49 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.49 |
| ▸ | STK10 | O94804 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | PAK4 | O96013 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | INSR | P06213 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | YES1 | P07947 | 1/20 | 0.49 |
| ▸ | LYN | P07948 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | HCK | P08631 | 1/20 | 0.49 |
| ▸ | BCR | P11274 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1792868 | 0.99 | IGF1R (0.65) | IGF1RBMPR1BPLK4AURKAEPHB6 | |
| SCHEMBL1788516 | 0.94 | IGF1R (0.67) | IGF1RBMPR1BPLK4AURKAEPHB6 | |
| SCHEMBL1792487 | 0.89 | IGF1R (0.64) | IGF1RNTRK1 | |
| SCHEMBL1790299 | 0.88 | IGF1R (0.58) | IGF1RBMPR1BPLK4AURKAEPHB6 | |
| SCHEMBL1788757 | 0.86 | IGF1R (0.64) | IGF1R | |
| SCHEMBL1793551 | 0.85 | IGF1R (0.65) | IGF1RBMPR1BPLK4AURKAEPHB6 | |
| SCHEMBL1791491 | 0.84 | IGF1R (0.64) | IGF1RBMPR1BPLK4AURKAEPHB6 | |
| SCHEMBL1795880 | 0.83 | IGF1R (0.66) | IGF1RBMPR1BPLK4AURKAEPHB6 | |
| SCHEMBL1792170 | 0.79 | IGF1R (0.63) | IGF1RBMPR1BPLK4AURKAEPHB6 | |
| SCHEMBL4468090 | 0.78 | IGF1R (1.00) | IGF1RBMPR1BPLK4AURKAEPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222256-B2 | Methods of using IGFIR and ABL kinase modulators | EXELIXIS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20090232828-A1 | Methods of Using IGFIR and ABL Kinase Modulators | EXELIXIS, INC. (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090232828-A1 | Methods of Using IGFIR and ABL Kinase Modulators | IGF1R, ABL2, ABL1 | IGF1R 1/4885BMPR1B 980/4885PLK4 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.